Intensity Therapeutics, Inc. vs Innate Pharma S.A. — Valuation Comparison 2026
Access all valuation models for INTS vs IPHA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →IPHA scores higher with a 4.8/10 quality rating vs INTS's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Intensity Therapeutics, Inc. (INTS) and Innate Pharma S.A. (IPHA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
INTS currently trades at $4.42 with a QOC of 3.7/10, while IPHA trades at $1.74 with a QOC of 4.8/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).